Cancer from A to Z

Types of cancer, how to prevent them, diagnosis and treatment.


Kidney Cancer

Renal carcinoma affects approximately 9 persons per year for each 100.000 persons in Spain.

About half of new cases diagnosed in adults are localized, or limited to the kidney itself. Another 25% have advanced kidney cancer at diagnosis, and 25% will have regional kidney cancer. Ultimately, about half of kidney cancer patients will experience metastases (tumor spread). The risk of metastasis is directly related to the size of the primary tumor. 


In the 1980s, up to 80% of people had advanced kidney cancer when diagnosed. Today, thanks to advanced detection methods, only about 40% of patients have advanced kidney cancer at diagnosis.



Types of Kidney Cancer

Renal cell carcinoma (RCC) is the most common type of kidney cancer. Types of RCC include clear cell, papillary, chromophobe and collecting duct carcinomas. Clear cell carcinoma accounts for 80% of all RCC cases, and most treatments are focused on this type.


Wilms’ tumor is a childhood cancer, responsible for 95% of pediatric kidney cancer cases.

Due to the location of the kidneys, people often don't experience any symptoms until the tumor has grown quite large. The most common symptom is blood in the urine (hematuria), but the presence of blood doesn't necessarily mean it is cancer.


Other kidney cancer symptoms may include:

  • A lump or mass in the kidney area
  • Recurrent fever
  • Rapid weight loss
  • Lingering dull ache or pain in the side, abdomen or lower back
  • Feeling fatigued or in poor health

Having one or more of the symptoms listed above does not necessarily mean you have kidney cancer. However, it is important to discuss any symptoms with your doctor, since they may indicate other health problems.


At the moment there are no courses of Kidney Cancer

Clinical trials
Ensayo clínico fase 3, Multicéntrico, abierto, aleatorizado, que compara la eficacia y seguridad de Lenvatinib en combinación con everolimus o pembrolizumab y Sunitinib solo en primera línea de tratamiento de sujetos con cáncer renal avanzado.
Ensayo de fase 1a/2a, abierto y multicéntrico, para investigar la seguridad, tolerabilidad y actividad antitumoral de dosis repetidas de Sym015, una mezcla de anticuerpos monoclonales dirigida frente al receptor MET, en pacientes con tumores malignos sólidos en fase avanzada
Ensayo en fase III, multicéntrico, randomizado, placebo control de atezolizumab(MPDL3280A, anticuerpo anti-PDL1)en combinación con QT basada en platino en pacientes en carcinoma urotelial localmente avanzado o metastásico
Estudio fase 2, aleatorizado y abierto para evaluar la seguridad y eficacia del tratamiento en monoterapia MLN0128 y la combinación de MLN0128 + MLN1117 versus tratamiento con Everolimus en adultos con cáncer avanzado o metastásico de células claras renales que han progresado al tratamiento con VEGF- terapia dirigida. (Sunitinib ó Pazopanib)
Estudio fase IIIB, prospectivo, randomizado, abierto que evalúa la eficacia y seguridad de Heparina/Edoxaban versus Dalteparina en tromboembolismo venoso asociado con cáncer.
Estudio de fase III internacional randomizado de inmunoterapia con células dendríticas autologas (AGS-003) más tratamiento estándar en cáncer de células renales avanzado (ADAPT)
Tumores sólidos. Antiemesis Estudio fase III, multicéntrico, aleatorizado, doble ciego, con control activo para evaluar la seguridad y eficacia de Rolapitant en la prevención de náuseas y vómitos por la quimioterapia (NVIQ) en pacientes que reciben quimioterapia altamente emética (QAE). A phase III, multicenter, randomized, double blind, placebo controlled study of the safety and efficacy of Rolapitant for the treatment of Chemotherapy-induced nausea and vomiting in subjects receiving highly Emetogenic Chemotherapy (HEC)
Ensayo clínico en fase I de determinación de dosis del antiangiogénico multidiana Dovitinib (TKI258) más paclitaxel en pacientes con tumores sólidos.
Estudio fase III aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de Pazopanib como tratamiento adyuvante en sujetos con carcinoma de células renales localizado o localmente avanzado tras nefrectomía

The most significant risk factor for kidney cancer is smoking. Other risk factors include:

  • Age: Most cases occur after age 50
  • Gender: Men are more than twice as likely to get kidney cancer as women
  • Obesity
  • On-the-job exposure to asbestos, cadmium and coke (used in making steel)
  • High blood pressure
  • Long-term kidney dialysis
  • von Hippel Lindau disease

There are several tests used to detect and stage kidney cancer:


Imaging studies such as a CT scan, ultrasound, MRI or intravenous pyelogram (IVP). CT scans are very useful for detecting kidney tumors. IVP, which involves injecting a dye that shows up on an X-ray as it travels through the urinary system, can be helpful in diagnosing kidney cancer. These imaging studies can also be used for disease staging to help oncologists determine the appropriate treatment.


Fine Needle Aspiration (FNA) involves the insertion of a long, thin needle into the kidney to take a tiny sample of tissue (biopsy) for examination under a microscope. FNA is generally used if other tests have failed to prove the presence of a tumor.


Surgery to treat kidney cancer is called nephrectomy. Depending on the tumor size, location and stage, the surgical oncologist may choose to remove the entire kidney (radical nephrectomy) or just the portion affected by cancer (partial nephrectomy).


For advanced or metastatic kidney cancer, surgery can play a role along with other treatments.


Radical Nephrectomy

Radical nephrectomy involves removal of the entire kidney. There are two types of radical nephrectomy:

Standard or "open" surgery: a four- to five-inch incision is made in the lower back. The surgeon removes the entire kidney through the incision.


Laparoscopic Radical Nephrectomy (LRN): a small incision is made to insert a laparoscope, a thin tube with a camera that allows the surgeon to view the treatment field on a monitor. Other tiny incisions are made for miniature surgical instruments to remove the kidney. Its benefits include a shorter hospital stay (three days vs. one week), shorter recovery time and less blood loss than with open surgery.


Partial Nephrectomy

In a partial nephrectomy, only the cancerous portion of the kidney is removed, along with a margin of healthy tissue. Pre-treatment imaging is used to determine what will be removed, and ultrasound is used to look for additional tumors during surgery.


As with radical nephrectomy, this procedure can be done by traditional or laparoscopic methods. Laparoscopic partial nephrectomy (LPN) is still considered developmental.


Candidates for partial nephrectomy are chosen based on favorable tumorlocation, co-existing health problems that may affect the treatment outcome and the patient's desire to save their kidney. Partial nephrectomy is best for tumors four centimeters or less in size. Recurrence rates for both types of partial nephrectomy are about 5%.


Energy Ablative Techniques

Another minimally invasive surgery technique uses either heat or cold energy to treat tumors in place, without having to remove the kidney.


Cryoablation freezes the tumor to -150 degrees Centigrade with a long, thin probe inserted into the tumor. Intensive follow-up with X-rays or other imaging procedures is required to ensure that the tumorhas been destroyed. Cryoablation is ideal for smaller kidney tumors in patients considered at high risk for surgery.


Radiofrequency Ablation (RFA) is similar to cryoablation, but heat is used to kill the tumor instead of cold. RFA does have good potential for appropriate patients.


Radiation Therapy

Radiation has a limited role in the treatment of kidney cancer. Kidney tumors are not very sensitive to radiation, but healthy kidneys are, so radiation as a frontline treatment isnot viable.


In some cases, radiation may be used as a palliative treatment, to ease pain and other symptoms of advanced kidney cancer that has spread to bone or other areas of the body.



Chemotherapy is generally ineffective against kidney tumors, but may have a role in the treatment of metastatic tumors that have spread to the lung, bones, brain or lymph nodes. In these cases, chemotherapy would be combined with surgery or other localized therapy. A combination of gemcitabine and capecitabine to treat metastatic renal cell carcinoma has been studied in several clinical trials, and other chemotherapy agents may also be analyzed for their effectiveness in treating metastases.



A significant amount of cancer research has been devoted to immunotherapy, which uses the body's own defense mechanisms to fight cancer. All cells have protein markers, called antigens, on their surfaces that identify them as either "normal" or "foreign." The presence of foreign antigens (such as cancer cells) provokes a sophisticated chemical reaction involving lymphocytes and other cells that defend the body against disease. Some of these defender cells produce antibodies, which seek out and destroy specific antigens.

Immunotherapies are designed to manipulate the antigen/antibodyimmune response by targeting antigens on specific types of tumor cells. As researchers identify more of these tumor-specific antigens, they are working to develop therapeutic agents that target only those cells.


There are two basic types of immunotherapy:


Antibody therapy targets specific antigens. Rituximab and Herceptin are examples of antibody therapies currently approved for treatment of certain types of lymphoma and breast cancer, respectively.


Cancer vaccines are designed to attack antigens that exist specifically on cancer cells. However, many of these proteins are also expressed on normal cells. MD Anderson researchers are trying to re-teach the immune system to recognize and eliminate tumor antigens without affecting normal cells.


Immunotherapy & Kidney Cancer

Renal cell carcinoma (RCC) is very responsive to immunotherapy, which has become the standard of care for metastatic disease. Two types of immunotherapy are used to treat metastatic RCC:


Interferon-alpha is a protein produced by white blood cells in response to a viral infection. It increases antigens on the surface of cancer cells, making them more susceptible to attack by the immune system. Interferon is an outpatient treatment administered via injection, which patients can do themselves. Side effects of interferon therapy include flu-like symptoms (fever, muscle aches, headache and nasal congestion), depression, fatigue and nausea.


Interleukin-2 (IL-2) is a protein that stimulates the growth of immune cells and activates them to destroy tumor cells. High-dose IL-2 therapy is administered intravenously, and treatment requires a five-day hospital stay. Side effects include hypotension (low blood pressure), flu-like symptoms (fever, muscle aches, headache and nasal congestion), decreased urine production, nausea and diarrhea.  

Both of these therapies have only a general, non-targeted effect on the immune system, and their intense side effects are not well-tolerated by many patients. Both therapies have about a 15% response rate, but those who do respond do so quite dramatically.


Targeted Therapy

Kidney tumors are very vascular (blood vessel-rich). They rely on a process called angiogenesis to create their own network of blood vessels, enabling the tumor to thrive and grow. These blood vessels have unique characteristics that may make them vulnerable to drugs designed specifically to target them without harming normal blood vessels.


A number of "anti-angiogenic" compounds have been developed to take advantage of the process, including bevacizumab (AvastinTM) and sorafenib (Nexavar®). These are merely examples of a growing field of treatments that target vulnerabilities specific to the tumor, with lower side effects than traditional chemotherapies or immunotherapies.